$5.3 Billion is the total value of RA Capital Management's 54 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 22.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Buy | ASCENDIS PHARMA A/S | $1,001,863,112 | +34.3% | 11,225,357 | +61.3% | 18.92% | +12.0% |
| LEGN | Buy | LEGEND BIOTECH CORP | $432,452,724 | +268.1% | 6,264,707 | +157.1% | 8.16% | +207.1% |
| PCVX | Buy | VAXCYTE INCsponsored ads | $394,089,225 | +44.2% | 7,891,254 | +8.2% | 7.44% | +20.3% |
| DICE THERAPEUTICS INC | $365,018,194 | +62.2% | 7,856,612 | 0.0% | 6.89% | +35.2% | ||
| ETNB | 89BIO INC | $216,351,165 | +24.4% | 11,416,948 | 0.0% | 4.08% | +3.8% | |
| BIIB | BIOGEN INCsponsored adr | $151,794,286 | +2.5% | 532,892 | 0.0% | 2.87% | -14.5% | |
| AVTE | AEROVATE THERAPEUTICS INC | $141,727,291 | -15.0% | 8,263,982 | 0.0% | 2.68% | -29.1% | |
| VRNA | VERONA PHARMA PLC | $133,562,309 | +5.3% | 6,317,990 | 0.0% | 2.52% | -12.2% | |
| CVAC | CUREVAC N V | $127,602,851 | +49.5% | 12,245,955 | 0.0% | 2.41% | +24.7% | |
| TYRA BIOSCIENCES INC | $123,236,812 | +6.0% | 7,236,454 | 0.0% | 2.33% | -11.6% | ||
| Buy | NEWAMSTERDAM PHARMA COMPANY | $107,010,000 | +101.8% | 9,000,000 | +125.0% | 2.02% | +68.2% | |
| Sell | CYTEK BIOSCIENCES INC | $105,022,537 | -14.6% | 12,297,721 | -8.1% | 1.98% | -28.8% | |
| JANX | JANUX THERAPEUTICS INC | $102,920,544 | -1.9% | 8,670,644 | 0.0% | 1.94% | -18.2% | |
| GERN | GERON CORP | $101,258,827 | +47.9% | 31,544,806 | 0.0% | 1.91% | +23.4% | |
| INBX | INHIBRX INC | $100,046,387 | +37.6% | 3,853,867 | 0.0% | 1.89% | +14.8% | |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $93,598,345 | -4.9% | 5,676,067 | +2.9% | 1.77% | -20.7% |
| DAWN | Buy | DAY ONE BIOPHARMACEUTICALS I | $93,249,633 | -0.9% | 7,809,852 | +10.9% | 1.76% | -17.4% |
| RXSIGHT INC | $87,920,525 | +72.7% | 3,052,796 | 0.0% | 1.66% | +44.0% | ||
| COGT | Buy | COGENT COMMUNICATIONS HLDGS | $75,967,180 | +17.4% | 6,416,147 | +6.9% | 1.43% | -2.1% |
| PEPGEN INC | $72,699,651 | -26.9% | 8,131,952 | 0.0% | 1.37% | -39.0% | ||
| AXSM | New | AXSOME THERAPEUTICS INC | $71,860,000 | – | 1,000,000 | +100.0% | 1.36% | – |
| RNA | AVIDITY BIOSCIENCES INC | $71,164,508 | -27.8% | 6,416,998 | 0.0% | 1.34% | -39.7% | |
| VOR | VOR BIOPHARMA INC | $70,294,039 | -42.6% | 22,748,880 | 0.0% | 1.33% | -52.1% | |
| GHRS | Buy | GH RESEARCH PLCsponsored adr | $66,293,706 | +48.7% | 5,587,333 | +0.1% | 1.25% | +24.1% |
| WVE | WAVE LIFE SCIENCES LTD | $62,615,313 | -15.9% | 17,202,009 | 0.0% | 1.18% | -29.9% | |
| ACRIVON THERAPEUTICS INC | $62,344,184 | +2.1% | 4,810,508 | 0.0% | 1.18% | -14.8% | ||
| ICOSAVAX INC | $59,218,200 | +71.2% | 5,963,565 | 0.0% | 1.12% | +42.8% | ||
| ITOS | ITEOS THERAPEUTICS INC | $58,484,509 | -2.7% | 4,417,259 | 0.0% | 1.10% | -18.9% | |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $55,466,425 | – | 3,069,531 | +100.0% | 1.05% | – |
| MINERALYS THERAPEUTICS INC | $54,193,016 | +8.9% | 3,178,476 | 0.0% | 1.02% | -9.2% | ||
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $48,225,310 | +33.2% | 4,691,178 | +0.1% | 0.91% | +11.2% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $47,769,035 | -6.5% | 2,007,946 | 0.0% | 0.90% | -22.0% | |
| ABOS | ACUMEN PHARMACEUTICALS INC | $46,997,418 | +18.5% | 9,770,773 | 0.0% | 0.89% | -1.2% | |
| ACRS | ACLARIS THERAPEUTICS INCsponsored ads | $45,611,958 | +28.2% | 4,398,453 | 0.0% | 0.86% | +6.8% | |
| IMGN | Sell | IMMUNOGEN INC | $43,966,307 | -47.6% | 2,329,958 | -89.3% | 0.83% | -56.3% |
| ENLIVEN THERAPEUTICS INC | $43,319,511 | -6.8% | 2,122,465 | 0.0% | 0.82% | -22.2% | ||
| FULC | FULCRUM THERAPEUTICS INC | $38,312,023 | +15.8% | 11,609,704 | 0.0% | 0.72% | -3.5% | |
| ELIEM THERAPEUTICS INCads | $36,822,377 | -3.4% | 13,150,849 | 0.0% | 0.70% | -19.5% | ||
| TENAYA THERAPEUTICS INC | $35,616,125 | +106.0% | 6,067,483 | 0.0% | 0.67% | +71.9% | ||
| AN2 THERAPEUTICS INC | $32,074,895 | -13.9% | 3,773,517 | 0.0% | 0.61% | -28.1% | ||
| PLRX | PLIANT THERAPEUTICS INC | $31,927,440 | -31.9% | 1,762,000 | 0.0% | 0.60% | -43.2% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $29,323,402 | +195.9% | 3,370,506 | 0.0% | 0.55% | +147.3% | |
| SBTX | ARS PHARMACEUTICALS INC | $20,164,843 | +2.9% | 3,009,678 | 0.0% | 0.38% | -14.2% | |
| HOWL | WEREWOLF THERAPEUTICS INC | $18,741,887 | +17.3% | 6,144,881 | 0.0% | 0.35% | -2.2% | |
| DSGN | DESIGN THERAPEUTICS INC | $18,718,755 | +9.2% | 2,971,231 | 0.0% | 0.35% | -9.0% | |
| SOLID BIOSCIENCES INC | $17,953,739 | +10.5% | 3,426,286 | 0.0% | 0.34% | -7.9% | ||
| BDTX | Buy | BLACK DIAMOND THERAPEUTICS I | $17,805,058 | +263.7% | 3,525,754 | +36.1% | 0.34% | +202.7% |
| NKTX | NKARTA INC | $17,093,233 | -38.3% | 7,805,129 | 0.0% | 0.32% | -48.5% | |
| CELC | CELCUITY INC | $15,372,011 | +7.1% | 1,400,001 | 0.0% | 0.29% | -10.8% | |
| IGMS | New | IGM BIOSCIENCES INC | $8,653,125 | – | 937,500 | +100.0% | 0.16% | – |
| CNTB | CONNECT BIOPHARMA HLDGS LTD | $7,899,833 | +13.0% | 6,991,003 | 0.0% | 0.15% | -5.7% | |
| TALS | New | TALARIS THERAPEUTICS INC | $7,092,852 | – | 2,333,175 | +100.0% | 0.13% | – |
| NSTG | Sell | NANOSTRING TECHNOLOGIESordinary shares | $6,979,661 | -71.3% | 1,723,373 | -29.9% | 0.13% | -76.0% |
| NEWAMSTERDAM PHARMA COMPANY | $696,666 | +13.6% | 333,333 | 0.0% | 0.01% | -7.1% | ||
| ENTX | Exit | ENTERA BIO LTD | $0 | – | -295,966 | -100.0% | -0.01% | – |
| FUSN | Exit | FUSION PHARMACEUTICALS INC | $0 | – | -659,992 | -100.0% | -0.06% | – |
| STSA | Exit | SATSUMA PHARMACEUTICALS INC | $0 | – | -5,914,252 | -100.0% | -0.09% | – |
| Exit | AADI BIOSCIENCE INC | $0 | – | -590,218 | -100.0% | -0.10% | – | |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -1,131,775 | -100.0% | -0.44% | – |
| KNTE | Exit | KINNATE BIOPHARMA INC | $0 | – | -4,264,144 | -100.0% | -0.60% | – |
| Exit | HILLEVAX INC | $0 | – | -1,760,019 | -100.0% | -0.66% | – | |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -1,734,972 | -100.0% | -1.41% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -12,643,574 | -100.0% | -2.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S - ADR | 38 | Q2 2024 | 25.5% |
| WAVE LIFE SCIENCES PTE LTD | 35 | Q2 2024 | 26.3% |
| TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
| ZOGENIX INC | 26 | Q4 2021 | 9.5% |
| RHYTHM PHARMACEUTICALS INC | 25 | Q2 2024 | 4.4% |
| BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
| DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
| ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
| 89BIO INC | 19 | Q2 2024 | 4.1% |
| KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Perceptive Capital Solutions Corp | June 24, 2024 | 750,000 | 8.4% |
| Aerovate Therapeutics, Inc. | June 20, 2024 | 9,242,092 | 32.0% |
| Evolent Health, Inc. | June 17, 2024 | 8,279,103 | 7.1% |
| Solid Biosciences Inc. | June 12, 2024 | 4,358,478 | 11.3% |
| BICYCLE THERAPEUTICS plc | June 07, 2024 | 2,253,000 | 5.0% |
| Tourmaline Bio, Inc. | June 03, 2024 | 2,045,028 | 8.0% |
| Structure Therapeutics Inc. | May 30, 2024 | 7,225,311 | 5.2% |
| iTeos Therapeutics, Inc. | May 14, 2024 | 3,659,046 | 10.0% |
| Medicenna Therapeutics Corp. | May 10, 2024 | 7,714,760 | 10.0% |
| Black Diamond Therapeutics, Inc. | May 09, 2024 | 2,788,028 | 5.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-09-03 |
| N-PX | 2024-08-30 |
| 4 | 2024-08-23 |
| SC 13G/A | 2024-08-23 |
| SC 13G | 2024-08-23 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-08-14 |
| 4 | 2024-08-13 |
| SC 13G/A | 2024-08-13 |
| SC 13G | 2024-08-12 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.